Perioperative gemcitabine + erlotinib plus pancreaticoduodenectomy for resectable pancreatic adenocarcinoma: ACOSOG Z5041 (Alliance) phase II trial
- Citation:
- Ann. Surg. Oncol. vol 26 (13) 4489-4497
- Year:
- 2019
- Type:
- Manuscript
- Funding:
- NCTN
- Endpoint:
- Primary
- Analysis:
- Primary
- Data Sharing:
- No-Data-Sharing
- Status:
- Presented/Published
- Citation Status:
- pmc-release
- Note:
- Methodological:
- No
- Biospecimen:
- No
- SDC:
- No
- Book Volume:
- 9
- Parents:
- 2903
- Children:
- None
- Pharmas:
- Grants:
- U10CA180821, U10CA180882, U10CA180791, U10CA180836, U10CA180858, U10CA180867
- Corr. Author:
- Authors:
- Alice C. Wei Fang-Shu Ou Qian Shi Xiomara Carrero Eileen M. O'Reilly Jeffrey Meyerhardt Robert A. Wolff Hedy L. Kindler Douglas B. Evans Vikram Deshpande Joseph Misdraji Eric Tamm Dushyant Sahani Malcolm Moore Elliot Newman Nipun Merchant Jordan Berlin Laura W. Goff Peter Pisters Mitchell C. Posner
- Networks:
- 11030, FL028, LAPS-IL057, LAPS-MA036, LAPS-MN026, LAPS-NY016, LAPS-TN008, LAPS-TX035, LAPS-WI013, NORTHWELL
- Study
- ACOSOG-Z5041
- Multiple Studies, or Legacy Studies in Alliance Study:
- Phases:
- 2
- Keywords:
- pancreas ductal adenocarcinoma, neoadjuvant, chemotherapy, resectability, pancreatectomy